Trodelvy^® (sacituzumab govitecan) Granted European Commission Marketing Authorization for Treatment of Metastatic Triple-Negative Breast Cancer in Second Line

Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® as a monotherapy indicated for the treatment of adult patients with unresectable or metastatic TNBC who have received two or more prior systemic therapies.